Age

18–99

Sex

ALL

Healthy volunteers

Not accepted

Patients with chronic kidney disease stages 3b-5 (eGFR: 10 - \<45 ml/min/1.73m²)
Patients with regular visits in the study sites to manage their chronic kidney disease (≥ 1 visit per 3 months during the past year before enrollment)
Willingness to participate in the study with signed informed consent

Patients already under kidney replacement therapy or will receive kidney replacement therapy in 6 months
Unwillingness or without the ability to monitor hyperkalemia using the study device
Patients with heart pacemaker implanted

Monitoring Hyperkalemia Using Point-of-care AI-enabled ECG Device Among Patients With Chronic Kidney Disease Stages 3b-5